Trial Profile

A Phase1a dose escalation and clinical drug-drug interaction study of NXP-900 in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NXP 900 (Primary) ; Bupropion; Caffeine; Midazolam
Indications Solid tumours
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

Most Recent Events

07 Nov 2025 New trial record
27 Oct 2025 According to a Nuvectis Pharma media release, company announced initiation of the combination portion (NXP900 and caffeine, bupropion and midazolam) in the near term and start providing clinical data updates as the program proceeds.
27 Oct 2025 According to a Nuvectis Pharma media release, company today provided highlights for NXP900 poster presentations that took place last week at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com